Holen Sie sich die Stockscreener-App
1.85
1.07%
-0.02
Handel nachbörslich:
1.85
Aldeyra Therapeutics Inc Aktie (ALDX) Neueste Nachrichten
Aldeyra Therapeutics And 2 More Promising Penny Stocks For Your Watchlist - Yahoo Finance
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra ... - Bluefield Daily Telegraph
Aldeyra receives FDA rejection for dry eye treatment reproxalap - MSN
Does Aldeyra Therapeutics (ALDX) have the potential to rally 79.28% as Wall Street analysts expect? - MSN
BTIG Reiterates Aldeyra Therapeutics (ALDX) Buy Recommendation - MSN
Rosen Law Firm Investigating Potential Securities Claims Against Aldeyra Therapeutics - National Today
ALDX Investor News: If You Have Suffered Losses in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), ... - Bluefield Daily Telegraph
ALDX Investor News: If You Have Suffered Losses in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.
ALDX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Rosen Law Firm Encourages Aldeyra Therapeutics, Inc. Investors to Inquire About Securities Class Action InvestigationALDX - Barchart.com
Insider Buying: Richard Douglas Acquires 70,000 Shares of Aldeyra Therapeutics Inc (ALDX) - GuruFocus
Aldeyra therapeutics director Douglas buys $98,000 in ALDX By Investing.com - Investing.com India
Insider Makes Bold Move on Aldeyra Therapeutics Stock - TipRanks
Insider Buying: Richard Douglas Acquires 70,000 Shares of Aldeyr - GuruFocus
Rosen Law Firm Encourages Aldeyra Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – ALDX - The Joplin Globe
ALDX PE Ratio & Valuation, Is ALDX Overvalued - Intellectia AI
Aldeyra therapeutics director Douglas buys $98,000 in ALDX - Investing.com
Director buys 70K Aldeyra Therapeutics (ALDX) shares at $1.40 - Stock Titan
Why Did ALDX Stock Tank 70% Today? - Stocktwits
ALDX crashes 71% as FDA issues third CRL for dry eye disease drug NDA - MSN
FDA rejects Aldeyra's dry eye drug for third time, stock crashes 68% - MSN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc.ALDX - PR Newswire
Aldeyra Therapeutics CFO Alfieri buys $7,100 in stock By Investing.com - Investing.com Australia
Insider Buying: Michael Alfieri Acquires Additional Shares of Al - GuruFocus
Aldeyra Therapeutics CFO Alfieri buys $7,100 in stock - Investing.com
Aldeyra Therapeutics (ALDX) finance chief buys 5,000 shares - Stock Titan
ALDX Investor Alert: Aldeyra Therapeutics, Inc. Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Management Allegedly Misrepresented Drug Efficacy And Approval Prospects - marketscreener.com
What's Going On With Aldeyra Therapeutics Stock On Thursday? - Benzinga
BTIG Maintains Buy on Aldeyra Therapeutics, Inc. (ALDX) March 2026 - Meyka
HC Wainwright & Co. downgrades Aldeyra Therapeutics (ALDX) - MSN
Aldeyra’s CEO to Lead Strategic Discussions at Healthcare Conference - StocksToTrade
Shareholder Alert: Ademi LLP Investigates Claims of Securities F - GuruFocus
Potential Securities Fraud: Levi & Korsinsky Investigates Aldeyra Therapeutics, Inc. (ALDX) - The Globe and Mail
Aldeyra Eyes Growth as CEO Prepares for Key Conference - timothysykes.com
Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud against Aldeyra Therapeutics, Inc. - Barchart.com
Aspen’s fresh Parkinson’s data; Aldeyra tanks following FDA rejection - BioPharma Dive
ALDX Plummets 71% Following FDA's Third Complete Response Letter for Dry Eye Disease Drug Application - Bitget
ALDX Crashes 71% as FDA Issues Third CRL for Dry Eye Disease Drug NDA - The Globe and Mail
Upcoming Conference Sheds Light on Aldeyra Therapeutics’ Innovations - StocksToTrade
Aldeyra shares plunge after third FDA rejection for reproxalap - The Pharma Letter
BTIG Maintains Aldeyra Therapeutics(ALDX.US) With Buy Rating, Maintains Target Price $9 - 富途牛牛
This Trade Desk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
ALDX Stock Downgraded by HC Wainwright & Co. with Price Target R - GuruFocus
H.C. Wainwright cuts Aldeyra stock rating on FDA setback - Investing.com
HC Wainwright Downgrades Aldeyra Therapeutics to Neutral From Buy, Adjusts PT to $2 From $10 - marketscreener.com
FDA issues CRL to Aldeyra’s reproxalap drug application - Yahoo Finance
Aldeyra Therapeutics (ALDX) Is Down 75.2% After FDA Rebuffs Dry Eye Drug Efficacy DataHas The Bull Case Changed? - simplywall.st
FDA rejects Aldeyra’s dry eye disease drug application By Investing.com - Investing.com South Africa
FDA Issues Complete Response Letter to Aldeyra Therapeutics for Dry Eye Drug Reproxalap - geneonline.com
Aldeyra Therapeutics (ALDX) Faces Major Setback as FDA Rejects E - GuruFocus
Aldeyra Therapeutics stock maintained at Buy by BTIG after FDA setback - Investing.com South Africa
Aldeyra Therapeutics stock plunges 70% after third FDA rejection - The Business Journals
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):